Most newborns in the neonatal intensive care unit (NICU) are premature and at risk of invasive fungal infections (IFIs). Invasive yeast infections (IYIs) are the most common fungal infections in this population. These infections are difficult to diagnose because symptoms are nonspecific, and the sensitivity of blood cultures is low. The serum (1,3)-β-D-glucan (BDG) assay provides a reliable marker for the diagnosis of IFIs in adults with haematological malignancies. We assessed the diagnostic performance of this test in neonatal IYIs and its contribution to the monitoring of antifungal treatment. A retrospective study was performed in the NICU of the French University Hospital of Amiens from February 2012 to February 2014. Forty-seven neonates (33 males, 14 females) with a median gestational age of 30 weeks (IQR: 27-31) and median birth weight of 1200 g (IQR: 968-1700) were included and divided into three groups: 21 control neonates (CTRL), 20 neonates with probable IYI (PB), and six with proven IYI (PV). Median BDG levels were significantly higher in the global IYI group (PB + PV): 149 pg/ml (IQR: 85-364) vs. CTRL group: 39 pg/ml (IQR: 20-94) (P < .001). The optimal cut-off was 106 pg/ml (sensitivity 61.5%; specificity 81%). BDG levels decreased with antifungal treatment. BDG was detectable in cerebrospinal fluid, but the interest of this for diagnostic purposes remains unclear. Our results suggest that the BDG assay may be useful for the early identification of IYIs in neonates and for monitoring antifungal therapy efficacy.
risk factors have been identified, but prematurity is one of the mostly frequently reported in the literature. Premature neonates have an immature cutaneous and mucous epithelium and disrupted mechanical barriers. Furthermore, they are not able to mount an effective immune response due to the low number of functional polymorphonuclear leukocytes, low levels of soluble mediators including cytokines and complement fractions, and delayed adaptive immunity. 2 Approximately 36% of neonatal mortality worldwide may be related to invasive infections. 3 Early onset infections, which occur in the first 72 h after birth, are considered to have been transmitted from the mother to the neonate. When they appear more than 72 h after birth, they are considered to be late onset infections and are usually nosocomial in origin. Although neonatal infections are most frequently caused by bacteria, 4, 5 fungal infections in these populations are not uncommon and are associated with high rates of morbidity and mortality. 6, 7 Different fungal species are responsible for neonatal infections, but yeast infections, particularly those due to Candida spp., are the most common. 8 According to an epidemiological survey carried out in North America between 1997 and 2000, invasive candidosis (IC) represented 2.7% of early onset infections and 10.5% of late onset infections. 5 Death was observed in 28-41% of cases of IC. 5, 9 In a French epidemiological report published in 2013, the incidence of candidaemia was 2.2 per 100 000 infants per year, with a mortality rate of 25% in infants <28 days of age. 10 In neonates, IC may also have long-term neurological consequences. 11 Because of its nonspecific symptomatology, IC is difficult to diagnose. 1, 12 The sensitivity of culture of normally sterile sites, which is the gold standard, is lower in neonates than in adults, and several alternative nonculture-based strategies have been developed. These allow a diagnosis even in the presence of prophylactic or empiric antifungal therapy. The detection of fungal DNA in serum or whole blood by polymerase chain reaction mainly targets portions of ribosomal DNA sequences, such as ITS regions, and allows the identification of Candida spp. with a good compromise between sensitivity and specificity. 13, 14 Other approaches include the detection of fungal cell wall polysaccharides such as mannan and (1,3)-βD-glucans (BDG) as biomarkers of IC. Many studies have been carried out on the detection of serum mannan, and this assay may be performed in association with anti-mannan antibody detection to improve the sensitivity of IC diagnosis. 15, 16 However, the usefulness of mannan detection in clinical practice is still open to debate. [17] [18] [19] Furthermore, few studies have been carried out in neonates. 20 A more recent assay for the detection of BDG in serum (Fungitell R ) has been developed, which relies on the ability of amoebocyte lysates from Limulus polyphemus to detect fungal BDG after neutralization of the factor C pathway. The diagnostic performance of this biomarker has been studied extensively in adults in intensive care (ICUs) and oncohematology units, [21] [22] [23] [24] but little information is available about the performance of this test in pediatric patients and neonates. [25] [26] [27] [28] Since 2013, the detection of BDG in cerebrospinal fluid (CSF) has been studied in different types of invasive fungal infection (IFI) including aspergillosis, cryptococcosis, histoplasmosis, and IC in adults, children, and a small number of infants. [29] [30] [31] [32] [33] [34] [35] In premature infants, invasion of the central nervous system by Candida leads to haematogenous Candida meningo-encephalitis, which occurs in 15-20% of cases of IC and may contribute to increased mortality and long-term neurodevelopmental abnormalities. 36 The imaging features of this syndrome are not specific, and culture of CSF is known to lack sensitivity. The detection of CSF BDG would be of interest in this population. The aim of this study was to assess the performance of the BDG test in serum and CSF for the diagnosis and monitoring of invasive yeast infections (IYIs) in the neonatal ICU (NICU).
Materials and methods

Study population
This retrospective study included neonates with available BDG serum measurements admitted to the NICU of the French University Hospital of Amiens between March 2012 and February 2014. The BDG assay was indicated in patients displaying symptoms of sepsis according to Hundalani et al., 8 and for whom a blood culture and colonization screening were performed systematically. Patients were excluded if there was a lack of biological or clinical data (blood culture or colonization screening were not performed or access to the patient's file was restricted). Patients with other suspected IFIs such as Pneumocystis pneumonia or invasive aspergillosis were also excluded. All patients were exposed to the same risk factors and exhibited symptoms of sepsis. At least one blood culture and colonization screening (four body sites: skin, digestive tract, respiratory tract, and urine) were performed in all patients included in the study. 
Measurement of (1,3)-beta-D-glucan
Serum and CSF BDG determinations were performed on each sample in duplicate using the Fungitell R assay kit (Associates of Cape Cod Inc., East Falmouth, MA, USA) as recommended by the manufacturer. Briefly, a kinetic colorimetric assay performed at 37
• C was read at 405 nm for 40 min. The concentration of BDG in each sample was calculated automatically using a calibration curve with standard solutions ranging from 6.25 to 100 pg/ml.
Statistical analysis
Continuous variables are described as median and interquartile range (IQR: 25th percentile to 75th percentile). Categorical variables are described as percentages. Potential inter-group differences were assessed using the χ 2 test
(for categorical variables) or Mann-Whitney test (for two group comparison of quantitative variables). For the three group comparisons, analysis of variance was performed using the Kruskal Wallis test followed by the Dunn test in the case of intergroup differences. A receiver operator characteristic (ROC) curve was used to determine the ability of the serum BDG level to discriminate neonates with IYI from CTRL neonates. Sensitivity and specificity were calculated to determine the optimal BDG cut-off. A P value <.05 was considered statistically significant.
Results
Characteristics of the study population
Forty-seven neonates (33 male, 14 female) with a median gestational age of 30 weeks (IQR: 27-31) and median birth weight of 1200 g (IQR: 968-1700) were included. Six neonates had proven IYI (PV group), 20 had probable IYI (PB group), and there were 21 control neonates (CTRL group). The obstetric history, clinical characteristics, and care of the different groups are shown in Table 1 . Data concerning the risk factors for IYI in the neonates were collected and only prior surgery was found to be significantly higher in the PV group (66.7%) vs. CTRL group (9.5%) (P = .011) ( Table 1) . Mortality was not reported because of the lack of data; many of the neonates were transferred to peripheral hospitals and were lost to follow-up. However, the median duration of stay at our hospital for the CTRL, PB, and PV groups was 35 (IQR: 28-49), 42.5 (IQR: 27-56), and 66 (IQR: 64-107) days, respectively. The differences between the groups were not statistically significant. Among the six PV neonates, four (66.7%) were premature, two had an extremely low birth weight (<1000 g), and one had a very low birth weight (1000-1499 g).
Isolates
Of the six PV neonates, four had candidaemia due to C. albicans and two had M. pachydermatis fungemia. All of these neonates had digestive tract yeast colonization. In the PB group, all neonates were colonized in their digestive and/or urinary tract, and 14 had colonization of their respiratory tract and/or skin. Twelve patients were colonized with C. albicans, seven with M. pachydermatis, and one with C. parapsilosis. Two PV neonates, two PB neonates, and 10 CTRL neonates had coagulase-negative Staphylococcus bacteraemia, and Escherichia coli bacteremia was detected in one CTRL neonate.
Biological markers of inflammation
No neonate had leukopenia (white blood cell count < 1500/mm 3 ). The median white blood cell count was higher in the IYI groups (PB, 21 950/mm 3 ; PV 19 700/mm 3 ) than in the CTRL group (10 800/mm 3 ), with a significant difference between the IYI (PB+PV) and CTRL groups (P = .003). No significant differences were observed between the groups in terms of platelet count or CRP levels. The procalcitonin assay was performed too rarely to enable any comparisons.
Serum (1,3)-beta-D-glucan levels
The median serum BDG level was higher in the IYI groups (PB group: 117 pg/ml (IQR: 77-253); PV group: 4529 pg/ml (IQR: 1325-10 683); PV + PB group: 149 pg/ml (IQR: 85-364) vs. CTRL group: 39 pg/ml (IQR: 20-94); P = .029, P < .001, and P < .001, respectively) (Fig. 1) . The ROC curve (Fig. 2) The median serum BDG value in invasive malasseziosis was 95 pg/ml (IQR: 53-160) and was not significantly different from that observed in the CTRL group (39 pg/ml; IQR: 20-94) (P = .127) (Fig. 3) , whereas the median value for IC alone was 251 pg/ml (IQR: 93-378) (P = .001 vs. CTRL group). Analysis of IC alone led to an area under the ROC curve of 0.82 [95% CI: 0.68-0.96] (P = .0007) and an improvement in the sensitivity from 73% to 82.3% for an optimal cut-off of 86 pg/ml. The contribution of serum BDG to the early diagnosis of IFI could not be assessed for all neonates as early serum sampling was only available for two PV patients. For both of these, serum BDG was positive several days before the isolation of yeasts from blood culture (3827 pg/ml (−3 days before blood culture) and 90 pg/ml (−10 days before blood culture).
(1,3)-Beta-D-glucan measurement in CSF
CSF BDG values were available for four neonates (three PV and one PB) and the results of serial sampling were available for one. All of these neonates had at least one CSF sample with BDG levels > 400 pg/ml. For two neonates, BDG values were higher in CSF than in serum. Among the neonates with high levels of CSF BDG, only one had clinical symptoms and cerebral lesions observed by echography. In this case, BDG values in CSF were consistently lower than in serum ( Table 2) .
Evolution of serum (1,3)-beta-D-glucan levels with antifungal therapy
In order to evaluate the impact of antifungal therapy on the evolution of glucanaemia, values of serum BDG before and after the initiation of antifungal therapy were compared. Due to the retrospective nature of this study, serum results before and after antifungal therapy were only available for nine patients (three PV and six PB). The antifungal therapy duration varied from 17 to > 140 days. A decrease in serum BDG values was observed in all patients. Median serum BDG value decreased significantly with antifungal treatment from 322 pg/ml (IQR: 146-491) to 34 pg/ml (IQR: 21-42) (P = .004) (Fig. 4) . None of these patients died during the hospital stay at our institution. All of these patients were either transferred to another hospital or went home.
Influence of yeast colonization and bacteraemia on serum BDG levels
A colonization score was established according to the number of body sites colonized by yeast species (1 point for one positive site). Among the four investigated body sites, the colonisation score was 1/4 (n = 3 patients); 2/4 (n = 6); 3/4 (n = 9), and 4/4 (n = 1). No correlation was observed between colonization score and serum BDG levels for the neonates belonging to the PB group (r = −0.034; P = .886).
There was no significant difference in median serum BDG levels between neonates with a colonization score = 1 (257 pg/ml, IQR: 144-290) and those with higher colonization scores (107 pg/ml, IQR: 84-160) (P = .69). Similarly, there was no significant difference in median serum BDG levels in the CTRL group in the presence (n = 11) (52 pg/ml, IQR: 22-102) or absence (n = 10) (35 pg/ml, IQR: 28-94) (P = .52) of bacteraemia.
Discussion
Although neonatal IYIs are rare, their incidence is higher in premature neonates where they increase neurological impairment and mortality. 6, 11 In these patients, diagnosis of IYI is often delayed and is associated with a poor outcome. 7, 37 Growth of yeasts in blood cultures lacks sensitivity (<50%) and is dependent on the volume of blood sampled and repeated sampling, 38 which is difficult to perform in neonates. In this context, it is inadvisable to wait for evidence of candidaemia before initiating antifungal therapy. 39 The use of nonculture-based methods is important in the surveillance of patients at high risk of IFI. These methods should be easy to implement even with low volumes of serum and enable the detection of fungal-derived molecules including cell wall glycans or DNA in biological samples.
Even though there is no consensus regarding the use of these biomarkers, they are often used to determine the possibility/probability of IFI and consequently to help physicians identify patients who may require antifungal treatment. Several infectious disease experts recommend the use of the BDG assay for the diagnosis of IC in adults. 24, 40 Karageorgopoulos et al. carried out a meta-analysis of the BDG assay, which revealed a sensitivity of 57-97% and specificity of 56-93% 21 for the diagnosis of IFI. Considering the minimum delay in obtaining the BDG result (<2 h) and the small volume of serum required (10 μl), BDG monitoring appears to be appropriate for the screening of IFI in neonates. Among the studies published in pediatric patients, only two have assessed the diagnostic value of this assay in the setting of the NICU. 27, 28 In the present study,
we evaluated the contribution of serum and CSF BDG to the diagnosis of IYI by including a control group exposed to the same risk factors as the IYI patients. Our analysis of the risk factors for the development of IC 41, 42 showed that only prior surgery had an impact on the occurrence of IYI. Unexpectedly, our NICU patients with IYIs had a higher white blood cell count than neonates with bacteremia. In contrast to the findings of Zhao et al., thrombocytopenia was not observed in any of our neonates with IYIs. 43 In a previous study, Smith et al. showed that healthy children had higher serum BDG levels than healthy adults (68 vs. 48 pg/ml) 44 and suggested that the BDG threshold should be reevaluated for specific populations before its implementation in clinical practice. Our study revealed that serum BDG levels were higher in the IYI groups than in the CTRL group, with very high levels in the case of fungaemia, as reported previously. 25, 26, 28 Our results showed a sensitivity and specificity of 76.9% and 66.7% for a cut-off of 80 pg/ml as recommended by the manufacturer. In order to improve the specificity to 81% without impairing sensitivity, a new cut-off of 105 pg/ml was determined from the ROC curve. As the prevalence of fungaemia in the NICU of our hospital has not been established, it was difficult to estimate the positive predictive value (PPV) and negative predictive value (NPV). Regardless of the prevalence of fungaemia, the estimated PPV and NPV for fungaemia in our study was 74.1% and 70%, respectively, and the PPV and NPV for candidaemia alone was 66.7% and 82.4%, respectively. By considering fungemia and candiduria as criteria for IC, Goudjil et al. obtained an optimal cut-off of 125 pg/ml 28 for the diagnosis of IC in NICU patients. For IC alone, we observed an improvement in the sensitivity from 73% to 82.3% for an optimal cut-off of 86 pg/ml (AUC: 0.82 [95% CI: 0.68-0.96]). For the diagnosis of malasseziosis, applying the manufacturer's cut-off of 80 pg/ml, the sensitivity and specificity were 56.3% and 69.1%, respectively.
In a study by Mokaddas et al., pediatric oncology patients with fungal colonization had high BDG levels without any evidence of fungal infection, whereas noncolonized patients had negative glucanaemia. 45 However, no correlation was observed between BDG levels and yeast colonization in our present study.
Other studies in adults have demonstrated that serial positive BDG values increase the specificity of the test. 40, 46 In our study, the sensitivity and specificity were increased to 100% and 85.7%, respectively. However, only 16 patients had serial values, and nine patients had two consecutive positive values, making the results unreliable.
In addition to serum BDG, CSF BDG was also evaluated for the diagnosis of IYI. Despite the limited number of samples, it is worth noting that all patients with positive BDG in CSF also had high levels of serum BDG. Some experimental and clinical studies have suggested that the detection of BDG in CSF may be useful for the diagnosis of fungal meningitis. In a study of experimental meningitis after candidaemia in rabbits, CSF cultures were positive in very few cases (8.1%) although cerebral tissue damage was proven at autopsy, whereas CSF BDG levels were positive and were higher than serum levels. In this study, CSF BDG was considered a sensitive marker for the detection and therapeutic monitoring of meningeal candidosis. 47 In the present study, three neonates from the PV group had CSF BDG values > 80 pg/ml but CSF levels were lower than serum BDG values. Interestingly, one of these neonates had cerebral lesions revealed by echography, suggesting yeast dissemination to the brain. As reported previously for mannan 48, 49 or DNA, 50 these data suggest the usefulness of CSF BDG for the diagnosis of cerebral fungal lesions. 29, 30 As reported by Goudjil et al., 28 in the overall IYI group (PV and PB), serum BDG levels at the end of antifungal therapy were lower (median value 34 pg/ml) than before therapy (322 pg/ml) (Fig. 4) and may therefore reflect a reduced fungal burden. The individual outcome of our patients is not known because over 50% of our patients were transferred to another hospital. However, none of them died during their stay in our institution, and we can therefore assume that they were transferred only if they were clinically stable and needed less intensive care. These results do not match with published data in adults 51, 52 in whom BDG can persist at high levels and an increase in BDG during antifungal therapy may suggest a relapse. 23 These findings suggest different mechanisms of BDG clearance between adults and neonates. However, these results must be confirmed in a larger prospective study before drawing any firm conclusions. We also analyzed the decrease in BDG slope in patients treated with micafungin vs. fluconazole and no significant difference was observed (data not shown). A part of this study enabled us to assess BDG in Malassezia fungemia. Indeed, during the study, M. pachydermatis was isolated from several patients, mainly from peripheral body sites but also from blood cultures. In the present study, median serum BDG level in invasive malasseziosis (95 pg/ml) was lower than that observed in neonates with IC (251 pg/ml). This is probably related to the low expression of (1,3)-β-D-glucans in the cell wall of Malassezia spp. 53 These findings need to be investigated further to establish a more appropriate BDG cut-off for invasive malasseziosis and the management of these patients. Bacteremia has previously been reported as a cause of false BDG positivity. 54 All cases of bacteremia occurring during our study were caused by coagulase-negative Staphylococcus, the most frequent bacteria isolated in late onset sepsis in neonates, 3 except for one case that was caused by E. coli. We observed that BDG levels did not vary between patients with or without bacteremia. Even if this remains controversial in the literature, [54] [55] [56] our observations suggest that bacteraemia does not interfere with BDG determination in NICU patients. Other possible confounding factors, such as blood products, immunoglobulin infusion, surgery, or dialysis, have mainly been studied in adults, with contradictory results. [57] [58] [59] [60] We did not identify any confounding factors in our patients although not all data were recorded for all neonates as this was not one of our objectives. Our study has some limitations due to its monocentre and retrospective design, which may have led to bias. Indeed, the size of our population was very small, and we were limited by the transfer of many of our patients to peripheral hospitals preventing a more long-term analysis of our results (mortality, improvement under antifungal therapy). Furthermore, the BDG assays were not performed regularly at fixed time-points, and kinetics were not systematic. As the prevalence rates of IFI and IC in our NICU were not available, this study did not allow us to calculate the PPV and NPV. However, IYI is a rare event, which led us to predict a high NPV.
In conclusion, the results of our study on BDG detection for the diagnosis of IYI in neonates are encouraging and deserve to be evaluated further in a multicenter prospective study. This biological marker could be of particular interest in the case of a NICU patient with an intermediate pretest probability of IFI, especially as the quantity of serum required for testing is small and the result can be obtained rapidly. Moreover, measurement of BDG in CSF could be of real interest for the diagnosis and management of candidosis of the central nervous system. However, due to a number of difficulties in the interpretation of the BDG results, the test should only be performed by individuals who are aware of its limitations (such as confounding factors, microorganisms detected, etc.). Furthermore, interpretation of the results of the BDG test requires a dialogue between the physician and the microbiologist.
